Compounds > trans-4-methylcyclohexylamine
Page last updated: 2024-11-06

trans-4-methylcyclohexylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID80604
CHEMBL ID510738
CHEMBL ID3780789
CHEBI ID183280
SCHEMBL ID49052
SCHEMBL ID433619
SCHEMBL ID4456250
SCHEMBL ID10120393
SCHEMBL ID12021758
MeSH IDM0503610

Synonyms (111)

Synonym
AC-18739
BB 0259385
4-methylcyclohexan-1-amine
CHEBI:183280
nsc-32387
cyclohexanamine, 4-methyl-
p-methylcyclohexylamine
4-methylcyclohexylamine
6321-23-9
nsc32387
cyclohexylamine, 4-methyl-
trans-4-methylcyclohexylamine
inchi=1/c7h15n/c1-6-2-4-7(8)5-3-6/h6-7h,2-5,8h2,1h
4-methylcyclohexanamine
cis-4-methylcyclohexanamine
STK500609
M1780
2523-55-9
AKOS006348883
AKOS006345927
4-cis-methylcyclohexanamine
cis-1-amino-4-methylcyclohexane
bdbm50261173
1-amino-4-methylcyclohexane
M1117
CHEMBL510738 ,
4-methyl-cyclohexylamine
AKOS000120630
A5111
einecs 228-673-8
nsc 32387
cis-4-methylcyclohexylamine
2523-56-0
p-aminocyclohexylmethane
cyclohexanamine, 4-methyl-, cis-
AM804167
FT-0671631
trans-4-methyl-cyclohexylamine
FT-0607329
FT-0619076
FT-0623926
SCHEMBL49052
SCHEMBL433619
4-methylcylcohexylamine
KSMVBYPXNKCPAJ-KNVOCYPGSA-N
cis-4-methyl-1-cyclohexanamine
trans-4-methylcyclohexyl amine
(4-methylcyclohexyl)amine
trans-4-methyl-1-cyclohexanamine
trans 4-methylcyclohexylamine
trans 4-methylcyclohexyl-amine
KSMVBYPXNKCPAJ-LJGSYFOKSA-N
4-methylcyclohexylamine,c&t
4-methylcyclohexanamine #
SCHEMBL4456250
SCHEMBL10120393
DTXSID2064232
mfcd06411232
(1r,4r)-4-methylcyclohexanamine
trans-4-methylcyclohexanamine
W-104926
SCHEMBL12021758
cis-4-methylcyclohexylamine.
4ju ,
cyclohexanamine, 4-methyl-, trans-
cyclohexylamine, 4-methyl-, cis-
J-525026
CHEMBL3780789 ,
F0001-0850
mfcd00001495
trans-4-methylcyclohexylamine, aldrichcpr
cis-4-methyl-cyclohexylamine
trans-4-methylcyclohexan-1-amine
J-015882
bdbm50152094
AS-54788
cis-4-methyl cyclohexylamine
(1s,4s)-4-methylcyclohexan-1-amine
SY025288
trans 4-methylcylclohexylamine
mfcd13563117
AS-11818
M2949
BCP10473
BBL036898
SB36193
N13044
Q27453111
Q27454757
A902355
W10116
AS-78721
DTXSID601309835
DTXSID801307354
CS-0165194
(1r,4r)-4-methylcyclohexanamine? (glimepiride impurity pound(c)
(1r,4r)-4-methylcyclohexan-1-amine
EN300-145994
EN300-651151
AS-0806
(1r,4r*)-4-methylcyclohexan-1-amine
HZE5FWV7EQ
4-cis-methylcyclohexylamine
4-trans-methylcyclohexylamine
trans-1-amino-4-methylcyclohexane
6HY7JNM5XM
trans-4-methyl-1-cyclohexylamine
4-methylcyclohexylamine, trans-
4-methylcyclohexylamine, cis-
4-methylcyclohexylamine, mixture of cis and trans
EN300-20987
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amineA compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spermidine synthase, putative Trypanosoma cruzi strain CL BrenerIC50 (µMol)0.35650.09300.35650.6200AID1287123; AID1287125
Spermidine synthase Sus scrofa (pig)IC50 (µMol)1.70001.70001.70001.7000AID1287124
Spermidine synthase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)1.40001.40001.40001.4000AID384284
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1287125Inhibition of Trypanosoma cruzi strain CL Brener N-terminal poly-His tagged spermidine synthase expressed in Escherichia coli BL21(DE3) using 0.5 mM putrescine as substrate in presence of 1 mM dcSAM by FA-real time NMR analysis2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
An NMR Biochemical Assay for Fragment-Based Drug Discovery: Evaluation of an Inhibitor Activity on Spermidine Synthase of Trypanosoma cruzi.
AID1287124Inhibition of porcine spermidine synthase assessed as production of labeled 5'-methylthioadenosine using putrescine as substrate by enzymatic assay in presence of 10 uM decarboxylated AdoMet2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
An NMR Biochemical Assay for Fragment-Based Drug Discovery: Evaluation of an Inhibitor Activity on Spermidine Synthase of Trypanosoma cruzi.
AID1287123Inhibition of Trypanosoma cruzi strain CL Brener N-terminal poly-His tagged spermidine synthase expressed in Escherichia coli BL21(DE3) using 50 uM putrescine as substrate in presence of 100 uM dcSAM incubated for 1 hr by NMR analysis based constant-time 2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
An NMR Biochemical Assay for Fragment-Based Drug Discovery: Evaluation of an Inhibitor Activity on Spermidine Synthase of Trypanosoma cruzi.
AID384284Inhibition of Plasmodium falciparum spermidine synthase2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Identification of Plasmodium falciparum spermidine synthase active site binders through structure-based virtual screening.
AID384285Growth inhibition of Plasmodium falciparum2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Identification of Plasmodium falciparum spermidine synthase active site binders through structure-based virtual screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's3 (21.43)18.2507
2000's8 (57.14)29.6817
2010's2 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.0310sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
putrescine
[no description available]		2.0210alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		9.2250polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		9.2250polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		1.9810alpha-amino acid;
fluoroamino acid		trypanocidal drug
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		2.0510ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
n-butylamine
n-butylamine: RN given refers to parent cpd. butan-1-amine : A primary aliphatic amine that is butane substituted by an amino group at position 1.		2.0210primary aliphatic amine
n-(3-aminopropyl)cyclohexylamine
[no description available]		2.9140
alkenes
[no description available]		2.0210
ribavirin
Rebetron: Rebetron is tradename		2.04101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.0410adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		2.05103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
5'-methylthioadenosine
5'-methylthioadenosine: structure. 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.		2.0410thioadenosinealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.0210cysteiniumfundamental metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
American Trypanosomiasis
[description not available]		02.1310
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		02.1310
B-Cell Lymphoma
[description not available]		02.0510
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		02.0510
Weight Reduction
[description not available]		02.0210
Weight Loss
Decrease in existing BODY WEIGHT.		02.0210
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0310
Benign Neoplasms
[description not available]		02.9410
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.9410
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9810
Experimental Mammary Neoplasms
[description not available]		01.9810
Experimental Hepatoma
[description not available]		01.9810